

NC Medicaid and NC Health Choice Pharmacy Prior Approval Request for PCSK9 Inhibitors

Beneficiary Information

1. Beneficiary Last Name:	2. First Name	e:	
3. Beneficiary ID #:	2. First Name 4. Beneficiary Date of Birth:		5. Beneficiary Gender:
Prescriber Information			
6. Prescribing Provider NPI #:			
7. Requester Contact Information -			
Name:		Phone #:	Ext
Drug Information			
8. Drug Name:	9. Strength:	10. Quantity Per 30 Days:	
11. Length of Therapy (In days): □ u	p to 30 Days □ 60 Days □ 90 Days □	120 Days □ 180 Day	/s □ 365 Days □ Other
Clinical Information			
Clinical Questions for All PSC	CK9 Inhibitors:		
rosuvastatin (generic for Cress 3. Is the beneficiary's LDL level for Crestor) for 90 days? 4. Does the beneficiary have a serosuvastatin (generic for Cressignificant liver abnormalities, impairment, or mild aches. 5. Has documentation of clinical to this prior approval request? 6. Baseline LDL before statin tree. 7. LDL after statin treatment: **LDL lab results before and after statin tree.	king the maximum dose, for his/hetor) AND has completed 90 days ≥ 70mg/dl after taking atorvastaties □ No significant intolerance or allergic retor)? Examples of significant intolerance and rhabdomyolysis. Intolerance Yes □ No significant intolerance or allerge? □ Yes □ No seatment: □ Let statin treatment must be attackeneric for Lipitor) or rosuvastating	s of treatment? In (generic for Lipit reaction to atorvas plerance include see does not include it reaction to station to station to the does not include t	Yes No tor) or rosuvastatin (generic statin (generic for Lipitor) or evere muscle pain, fatigue, cognitive n treatment been attached oproval request**
10. Does the beneficiary have cl syndromes, or a history of m	nt: diagnosis of Heterozygous Familia inical atherosclerotic cardiovascu yocardial infarction, stable or unsulent ischemic attack, orperiphe	ular disease such a stable angina, cord	as acute coronary onary or other arterial



11. Does the beneficiary have a diagnosis of Severe P	rimary Hyperlipidemia (defined as
LDL-C ≥ 190mg/dL)? ☐ Yes ☐ No Clinical Question	s for Repatha:
12. Does the beneficiary have a diagnosis of Heterozyg	gous Familial Hypercholesterolemia (HeFH)? □ Yes □
No	
13. Does the beneficiary have a diagnosis of Homozyg	ous Familial Hypercholesterolemia (HoFH)? 🗆 Yes 🗆 No
14. Is the beneficiary 13 years or older? ☐ Yes ☐ No	
15. Does the beneficiary have clinical atherosclerotic c syndromes, or a history of myocardial infarction, st revascularization, stroke, transient ischemic attack	· ·
□ Yes □ No	
16. Does the beneficiary have a diagnosis of Severe P	rimary Hyperlipidemia (defined as
LDL-C ≥ 190mg/dL)? ☐ Yes ☐ No Continuation Que	estions for Praluent and Repatha:
17. Has the provider submitted documentation that indirequest? ☐ Yes ☐ No	cates a positive clinical response to therapy with this
18. Is the beneficiary continuing to receive other lipid-lo	owering therapy? Yes No
19. Is the beneficiary currently receiving more than one	PCSK9 inhibitor? □ Yes □ No
Signature of Prescriber:	Date:
(Prescriber Signature Mandatory)	

I certify that the information provided is accurate and complete to the best of my knowledge, and I understand that any falsification, omission, or concealment of material fact may subject me to civil or criminal liability.

Fax this form to (800) 678-3189 Pharmacy PA Call Center: (866) 799-5318